 NEWTON, Mass., July 13, 2021 GLOBE NEWSWIRE -- Allena Pharmaceuticals, Inc. NASDAQ: ALNA, a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has entered into definitive agreements with several healthcare-focused institutional and accredited investors for the purchase and sale of 21,357,744 shares of the Companys common stock or common stock equivalents and warrants to purchase up to an aggregate of 10,678,872 shares of the Companys common stock, at a purchase price of 1.311 per share of common stock or common stock equivalent and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. 